The Institute of Public Health (FHI) will drop the AstraZeneca vaccine because they believe the risk is too high. However, the government believes it is too early to take the vaccine out completely, and instead stacks in place a new group of experts who will be investigating both AstraZeneca and Johnson & Johnson further. In the professional basis of the FHI recommendation to the government, the risk of death and disease when vaccinated is weighed against other factors: ●Risk of disease and death of the coronavirus ●Postponement of the vaccination program; ●Infection situation ●Confidence in the vaccine Attention! FHI emphasizes that there are many reservations by their estimates. There is particular uncertainty as to how" common " the rare adverse reaction after vaccination with the AstraZeneca vaccine is. The situation of infection will also change the conditions. However, this estimate is highly uncertain and probably too high, including because it presupposes the widespread use of the AZ vaccine in several age groups. How to calculate the FHI risk of disease and death of AstraZeneca and covid-19: ●In Norway, five cases of serious post-vaccination events have been reported. ●Three of these have died. ●Ale received the symptoms seven to ten days after vaccination. ●They were between 32 and 54 years of age. The FHI has calculated the mortality rate (how many of the vaccinated people have died, Ed.amn.) in Norway at 2.3 people per 100,000 vaccinated. In Norway today, it will generally be at a greater risk to die by letting himself vaccinate with AstraZeneca-vaccine, than the risk of dying of covidsykdommen, according to FHI. "This means that we will expose younger women to an unreasonably high risk by offering the vaccine to this group, given the current level of infection in Norway," writes the Institute. Postponement of the vaccination These are some of the projections the FHI draws forward: ●For women in the age group 45-49 years, you must have a delay in vaksinasjonsprogrammet at 79 weeks that the risk to die of coronaviruset weigh up the risk of death by being vaccinated with AstraZeneca-vaccine. ●For women of the same age group, a seven-week delay in vaccination will result in the same risk of being admitted to an intensive care unit due to covid-19 disease as a risk of being admitted to an intensive care unit by vaccination with AstraZeneca. ●For men aged 65 to 69 years, a 5-week delay will present an equal risk of death from the vaccine adverse reaction as of covid-19. ●Men between 50-74 years of age will have approximately the same risk of being admitted to the intensive care unit if they take the vaccine out of the programme or if they keep it in the programme. The FHI believes, based on the analyses, that anyone who chooses this vaccine in Norway exposes himself to a greater risk of disease and death than waiting for another vaccine. Therefore, the institute would also not recommend that the vaccine be offered which is a voluntary offer: "We therefore believe that such an option may appear as unethical and with great risk that those who make such a choice have not understood the risk to which they expose themselves," writes the Institute. The FHI will ditch the AstraZeneca government postponing the decision. ** Infection situation.** The FHI emphasizes that the AstraZeneca vaccine provides good protection against covid-19 and that the serious side effects are rare. Therefore, the Institute weighs the situation of infection against the supposed risk of the AstraZeneca vaccine a decisive factor in the recommendation. FHI considers it so: ●Norway has control over the epidemic, with low infection rates. ●Norway has come a long way in vaccinating the elders and we have thereby reduced the risk of death in the most vulnerable. ●In Norway, in practice, it will be appropriate to use the vaccine at the younger age groups, because the elders are vaccinated or will be vaccinated in the near future. ●In the age groups remaining to vaccinate, the consequences of shifting vaccination from several to many weeks will nevertheless result in a lower mortality rate than vaccination with the AstraZeneca vaccine. In the scientific basis type FHI that there is reason to believe that a recommendation as to whether further use of the AstraZeneca-the vaccine could lead to lower confidence in the population to vaksinasjonsprogrammet in general. They emphasize that as of now it is not documented. "This could lead to a lower vaccination pace and vaccination rate in the long term, and that also patients at risk groups do not give thanks to vaccine.» At Week 13 to 14, the FHI conducted a survey in collaboration with Mindshare and Norstat, which showed that 76 percent were skeptical of at least one of the vaccines, although 82 percent were initially positive to vaccinate themselves. ●99 percent of them skeptical of AstraZeneca. ●15 percent of them were skeptical of Johnson & Johnson- ●Nine percent were skeptical of modern. ●Eight percent were skeptical of Pfizer. https://www.vg.no/nyheter/innenriks/i/lERn2A/derfor-ville-fhi-droppe-astrazeneca-vaksinenp https://www.vg.no/nyheter/innenriks/i/lERn2A/derfor-ville-fhi-droppe-astrazeneca-vaksinen